Categories Earnings, Health Care

Biocept narrows loss in Q4

Biocept (BIOC) narrowed its loss in the fourth quarter, beating analyst estimates. However, sales failed to impress the street. Shares of the firm increased above 3% after the bell as the Q4 loss came in better-than-expected.

Revenue saw a dip of 14% to $860,000 over the prior year, which came in below the Street consensus of $930,000. On a sequential basis, sales improved 7% in the fourth quarter. Net loss surpassed estimates in the Q4 touching $1.43 per share on 4.2 million weighted-average shares outstanding. Analysts were expecting losses for the diagnostics firm to be at $1.58 per share.

Last quarter, Biocept revenues dropped 31.5% to $761,591. However, net loss narrowed to $2.42 per share over $5.90 per share but failed to meet analyst consensus of $2.02 loss per share.

Commenting on the capital requirements CEO Michael Nall said, “We have raised more than $18 million in equity capital since the beginning of 2019, and we now believe that we have the financial resources to implement our business strategy throughout the year.”

Strategic Revamp  

Biocept also plans to launch multi-gene testing panel in the second quarter which is expected to lift the top line in the near future. The company believes that its Target-Selector platform can be commercialized as in vitro diagnostic (IVD) test kits. The platform provides biomarker detection and monitoring ability from patients’ blood sample for better diagnostics.

As part of its strategy, Biocept plans to market the Target-Selector platform to oncologists, pathologists, and physicians who use biomarker details for better diagnostics of their patients. The company plans to make money by offering lab services to biopharma companies to develop cancer drugs using its Target platform. In addition, licensing and sales of in-house testing and technologies to its global partners are also expected to generate revenues.

The diagnostics firm is also expanding its pathology partner program called Empower TC to pathologists throughout the United States. Launched in late 2017, this program helps pathologists to interpret biomarkers from blood samples of cancer patients locally. However, the specimens still need to be sent to its high-tech lab in San Diego, California.

Earlier this week, Biocept expanded its Empower platform to the urology market, which provides the ability to conduct biomarker tests in patients diagnosed with prostate cancer. Investors were upbeat about the news with the stock surging 13% post the announcement.

According to the American Cancer Society, 174,650 new cases are expected to be recorded in the USA for people who are suffering from prostate cancer. The organization also expects the USA to witness 31,620 deaths in 2019 just from patients with prostate cancer.

The early-stage cancer diagnostics company’s stock has increased 46% this year, recovering from the 52-week low levels of $0.66 recorded in December. Biocept’s share has lost about 86% in the last 12 months.

Listen to on-demand earnings calls and hear how management responds to analysts’ questions

 

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Comments

  1. Pingback: Beverly Bultron
  2. Pingback: Dental implants
  3. Pingback: Arab Region 2022
  4. Pingback: fue
  5. Pingback: first term exams
  6. Pingback: academic advising
  7. Pingback: ????? ??????
  8. Pingback: ????? ???????
  9. Pingback: Online Education
  10. Pingback: Dr. Hani Hassanein
  11. Pingback: torso rotary
  12. Pingback: Fiverr Earn
  13. Pingback: Fiverr Earn
  14. Pingback: Fiverr Earn
  15. Pingback: Fiverr Earn
  16. Pingback: Su HOOLED
  17. Pingback: fiverrearn.com
  18. Pingback: fiverrearn.com
  19. Pingback: ikaria juice buy
  20. Pingback: quietum plus
  21. Pingback: Freight Broker
  22. Pingback: fiverrearn.com
  23. Pingback: clima de hoy
  24. Pingback: fiverrearn.com
  25. Pingback: fiverrearn.com
  26. Pingback: fiverrearn.com
  27. Pingback: bernedoodle diet
  28. Pingback: morkie dog
  29. Pingback: jute rugs
  30. Pingback: Safe Piano Removal
  31. Pingback: best budget phones
  32. Pingback: future university
  33. Pingback: multisbobet
  34. Pingback: future university
  35. Pingback: lean six sigma
  36. Pingback: Safe moving
  37. Pingback: Classic Books 500
  38. Pingback: FiverrEarn
  39. Pingback: FiverrEarn
  40. Pingback: Streamer
  41. Pingback: FiverrEarn
  42. Pingback: pupuk organik
  43. Pingback: partners
  44. Pingback: nervolink health
  45. Pingback: Econometrics
  46. Pingback: FiverrEarn
  47. Pingback: FiverrEarn
  48. Pingback: live sex cams
  49. Pingback: FiverrEarn
  50. Pingback: FiverrEarn
  51. Pingback: FiverrEarn
  52. Pingback: FiverrEarn
  53. Pingback: FiverrEarn
  54. Pingback: digital marketing
  55. Pingback: landscape
  56. Pingback: Kuliah Termurah
  57. Pingback: FiverrEarn
  58. Pingback: FiverrEarn
  59. Pingback: FiverrEarn
  60. Pingback: cheap sex cams
  61. Pingback: live sex cams
  62. Pingback: Freeze dried
  63. Pingback: frt trigger
  64. Pingback: 늑대닷컴
  65. Pingback: Stacked symbol
  66. Pingback: nang sydney
  67. Pingback: superslot
  68. Pingback: allgame
  69. Pingback: 918kiss
  70. Pingback: หวย24
  71. Pingback: Korean Skincare
  72. Pingback: cybersécurité
  73. Pingback: judi slot
  74. Pingback: megagame
  75. Pingback: sicarios madrid
  76. Pingback: itsMasum.Com
  77. Pingback: nangs Sydney
  78. Pingback: nang tanks
Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top